Biopharmaceutical company Forte Biosciences Inc (NASDAQ: FBRX) on Monday reported additional data from its Phase 1b trial of FB102 in celiac disease, presented at the Tampere Celiac Disease Symposium in Finland on 12 September 2025.

FB102 reduced TCR γδ density by 1.5 from baseline compared to an increase of 3.9 on placebo (p=0.0007). Ki67-positive intraepithelial cell density, a marker of T cell proliferation, rose by 8.6 on placebo versus 2.5 on FB102 (p=0.0006). Natural killer cells declined by 95% with FB102, demonstrating inhibition of the IL-15 pathway, while no significant differences were observed in regulatory T cells between treatment and placebo.

Forte said the results reinforce the differentiated profile of FB102, its anti-CD122 monoclonal antibody in development for celiac disease and other autoimmune indications.